Our Faculty

Prof. Dr. Lieven Annemans has participated in more than 400 health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas. He has also been involved as an expert in a large number of Health Technology Assessments (HTAs) and is actively involved in HTA on a European level.

Lieven has a unique profile: academic professor, past-president of ISPOR, author of Health economics for non-economists (Pelckmans Pro, 2018), trainer and consultant.

Highly respected for his vast international and cross-therapeutic experience, Lieven is a much sought-after advisor and educator to health policy makers and the innovative healthcare industry.

Gary is the Founder & Chairman of Inpharmation, Europe’s most respected pharma forecasting & pricing specialist consultancy, and the author of "Value Pricing for Market Access: Evidence-Based Pricing for Pharmaceuticals" and "Sales Forecasting for Pharmaceuticals: An Evidence Based Approach".

Gary and his team have been involved in the pricing and/or forecasting of around half of the new molecular entity launches over the past 5 years.

Dr. Nick Proctor is a senior consultant to the pharmaceutical industry for over 20 years, most recently as a Partner with Access Infinity. Over the past 15 years, he has led pricing, reimbursement and access projects for the majority of the world’s top pharmaceutical brands and manufacturers.

Nick has a strong background in pricing, evidence synthesis, health economics and outcomes research, as well as experience of working with payers in all major developed and emerging international health markets.

Louisa Oliver Byrne leads Access Infinity’s US managed care centre of excellence team which brings advanced understanding and strategic impact of updates to the consulting team through training and advisory sessions. 

She is a highly experienced global pricing and market access consultant with over 7 years’ experience, having led numerous US managed care focused engagements to support brands of all sizes with their evidence generation plans, payer value stories and pricing for US commercial success. 

Louisa is an author of multiple peer-reviewed market access publications establishing burden, health utilities and treatment management approaches using approaches including TTO and Delphi. 

Maaike Addicks, MD is an independent Medical Affairs consultant with expertise in strategic Medical Affairs development, change management and Medical Affairs competency development.

She is a Board Member and currently Chair of the Medical Affairs Committee of the Dutch Association of Pharmaceutical Medicine (NVFG).

Maaike is a physician with over 15 years of on-the-job experience in Medical Affairs in mid-size and big pharma, in both headquarters and national affiliates, across a wide spectrum of therapeutic areas.

She has 10 years of experience in managing Medical Managers, Medical Advisors and MSLs, with both hands-on and strategic experience in Medical Affairs.

Ben Harbour is VP Global Accounts with Precision AQ (formerly Across Health), Europe's leading consultancy specialised in omnichannel customer engagement strategies for life science organisations. 

Ben is a strategic advisor to pharma, biotech and medical device companies on multi-channel communication programmes at the corporate, regional and brand level. 

He has extensive international experience spanning the clinical, medical and commercial phases of product development across a wide range of therapeutic indications. 

Chris Toller is a leading international consultant in pharmaceutical Medical Affairs who has worked with MA teams across the globe. 

Chris’ professional roles have included Managing Director at Choice Healthcare Solutions, Head of Strategy for the Choice Group, and Founder & MD of one of the UK’s first specialist medical communications agencies. Currently, he is Managing Partner at Havas Life Medicom UK. 

After his education as a physician, Chris built a career that has enabled him to work with Medical Affairs teams all over the world and in just about every therapy area. He has devised MA strategies and implemented programmes to support more than 50 medical brands on behalf of the world’s leading pharma companies. 

Dr. Patrik Frei is Founder & CEO of Venture Valuation, specialists in independent assessments and valuation of emerging high-growth companies in biotechnology and life sciences.

He is Europe’s top valuation expert of high-growth life science companies and author of Assessment and Valuation of High Growth Companies.

Patrik and his team carried out valuations for the Novartis Venture Fund.

He is the owner of Biotechgate, the global business development database for the life science industry.

Edouard Demeire is Visiting Professor at CEDEP (INSEAD) and author of KICCASS PHARMA – Keep it Customer Centric, Agile & Strategically Simple In Pharma & Diagnostic Management (2020).

He has contributed to the design of Roche’s and Novartis’ brand planning processes and runs courses for marketing and non-marketing audiences worldwide.

Edouard developed business simulations and decision support tools for the health care industry and trained tens of thousands of executives worldwide on pharma marketing strategy since 1990.

Dr. Roger Cox has 30 years of licensing experience encompassing both big and small pharma/biotech companies.

Currently Regional Advisor for UK and Europe with Plexus Ventures, Roger was formerly Executive Director with J&J’s Global Pharma BD Group where he negotiated over 50 commercial licence agreements.

Formerly a pharma BusDev & Licensing executive, David Scott has worked as a Senior BD&L Consultant since 1996.

He has concluded numerous inward and outward licensing agreements for clients covering small molecules, biologicals and delivery technologies.

David is the author of Scrip’s best-selling report Practical Guide to Pharmaceutical Licensing.

Dr. Carlos Velez is Founder and Managing Partner of Lacerta Bio, an international consultancy specialising in both in- and out-licensing of prescription and non-prescription product candidates and commercial products, across multiple therapeutic areas and markets.

Prior to that, Carlos built a 10+ years career in senior Business Development roles at Penwest Pharmaceuticals, Lantic Therapeutics Forest Labs, and Genencor (now Danisco).

Carlos has trained and consulted life science executives around the world on in- and out-licensing. 

Prof. Dr. Thomas Wilke has 25+ years of experience in leading and conducting European and German RWE studies, including database studies, linked data studies, medical chart reviews and surveys.

In addition to being an academic researcher and author of numerous articles, Thomas is leading the University-affiliated institute IPAM and acts as senior scientist at GIPAM, a consultancy specialised on European RWE studies.

James Turnbull is the Founder of the omnichannel-native medcomms agency Camino. Equipped with a computer science degree, he pioneered the application of artificial intelligence (AI) to medical affairs.

He has spoken on the use of AI at conferences from ISMPP, MAPS, and PING, and has frequently shared case studies and examples from his own experiences at the cutting edge of AI’s application to pharma challenges.

Throughout his more than fifteen years in leadership roles, James has helped healthcare brands grow and thrive through innovative solutions, earning many industry awards.

Manuel Mitola is Partner & Head of AI Consulting at ctcHealth, a specialist pharma consultancy focused on the transformation of marketing, sales and commercial excellence through the adoption of AI technologies.

His expertise is regularly showcased at various AI in Pharma conferences, and he actively shares case studies on his LinkedIn profile and YouTube channel. Manuel authored a chapter on AI for Pharma Marketing in the 2019 book "AI Marketing", published by HOEPLI. Additionally, he has trained numerous pharma managers, professionals and students in his role as a guest professor at IULM University (Milan).

During various marketing and digital innovation roles at Eli Lilly and Menarini, Manuel led the adoption of new technologies and capabilities, including AI. He has designed innovative omnichannel strategies and contributed to the successful launches of multiple brands in oncology and neuroscience.

Dr. Kristof Theys is a Health Economics and Data Science Manager at AxTalis from the MAP Group, a specialist pharmaceutical and biotechnology management consultancy focused on accelerating patient access to medicines, devices and diagnostics.

In his role within market access and medical affairs, he focuses on health economic modelling and the creation of decision support tools, while also leading analyses of real-world clinical data to further support patient access to innovative treatments.

Kristof holds an MSc in Bio-informatics, received a PhD in Biomedical Sciences from the KU Leuven and held various FWO mandates for post-doctoral research in clinical and epidemiological virology. 

As the founder and CEO of MArS Market Access & Pricing Strategy GmbH, Dr. Stefan Walzer initiated the application of AI platforms and tools in the area of market access to revolutionise dossier preparation, payer negotiations, and strategic decision-making.

Dr. Walzer's impressive career includes pivotal roles such as Global Payer Strategy Leader at F. Hoffmann – La Roche AG, author of over 40 peer-reviewed articles and 400 abstracts, as well as a recognised lecturer on market access, pricing, and negotiation at leading universities in Germany. 

Dr. Walzer holds a PhD in Health Economics from the University of Zurich, alongside qualifications from the University of Tuebingen and the London School of Hygiene and Tropical Medicine. 

Jean-Sebastien Struyf is Senior Strategy Consultant with Precision AQ (formerly Across Health), Europe's leading consultancy specialised in omnichannel customer engagement strategies for life science organisations. 

Before joining Across Health, Jean-Sebastien led (directly and indirectly) extensive teams at leading pharmaceutical companies, such as Novartis and Bristol-Myers Squibb, in a range of commercial and strategic roles in Belgium & Europe and in direct cooperation with global HQs, in the areas of marketing, salesforce effectiveness, and multichannel customer engagement. 

At Across Health Jean-Sebastien has worked on countless multi-channel projects for leading pharmaceutical and medtech companies across various therapeutic areas. 

Olga Duvillard is a senior consultant at Precision AQ (formerly Across Health) with over 8 years of experience navigating the landscapes of Multichannel and Commercial Excellence roles across Pharmaceutical and Software as a Service (SaaS) industries. Her true passion lies in shaping omnichannel customer engagement strategies for life science organisations.

At Precision AQ (formerly Across Health), Olga has supported clients specialising in both primary and secondary care, ranging from consumer healthcare to vaccines, respiratory treatments, and cancer drugs. Throughout the product lifecycle, she has built Omnichannel strategies for launch & growth products, as well as loss of exclusivity Omnichannel go-to-market models.

With her multi-country and multi-industry experience, Olga brings a deep understanding of customer needs and business priorities, enabling her to drive actions that enhance outcomes for patients, healthcare providers, and industry stakeholders.

As Board Director and Head of Research and Development, Sam leads the development of forecasting and pricing technologies at Inpharmation, Europe’s most respected pharma forecasting & pricing specialist consultancy.

Sam and the team at Inpharmation have been involved in the pricing and/or forecasting of around half of the new molecular entity launches over the past 5 years.

As an independent consultant, Kurt advises on commercial and launch excellence, drawing from his 20+ years of international experience within big and small pharma/biotech companies. 

Formerly, he was Global Launch Excellence Expert with Trilations, a strategic consultancy. 

Prior to that, Kurt led several major brand launches at MSD (Merck & Co), internationally and across several therapeutic areas. 

Stephen Marchant is Senior Strategy Consultant with Precision AQ (formerly Across Health), Europe's leading consultancy specialised in omnichannel customer engagement strategies for life science organisations. 

He is a healthcare industry leader in the omnichannel space with specific expertise in digital transformation, customer-centric strategies and impact measurement. 

Stephen has supported numerous cross-functional launch teams of leading pharma companies at both HQ and affiliate level. 

Jo Lopez is Practice Lead Early Commercialisation and Launch Excellence at Uptake, a global, value-driven independent healthcare consultancy focused on driving uptake across the pharma and biotech industry.

She is an international pharmaceutical leader with 20+ years of experience, specialising in launch excellence and early commercialisation.

Before joining Uptake, Jo held senior global launch roles at GSK and local commercial and market access roles at Roche.